APA
Bellmunt J., Esteban E., Del Muro X. G., Sepúlveda J. M., Maroto P., Gallardo E., Del Alba A. G., Etxaniz O., Guix M., Larriba J. L. G., Arranz J. A., Redrado M. & Calvo A. (20220201). Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. : European urology oncology.
Chicago
Bellmunt Joaquim, Esteban Emilio, Del Muro Xabier García, Sepúlveda Juan Manuel, Maroto Pablo, Gallardo Enrique, Del Alba Aranzazu González, Etxaniz Olatz, Guix Marta, Larriba Jose Luis González, Arranz Jose A, Redrado Miriam and Calvo Alfonso. 20220201. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. : European urology oncology.
Harvard
Bellmunt J., Esteban E., Del Muro X. G., Sepúlveda J. M., Maroto P., Gallardo E., Del Alba A. G., Etxaniz O., Guix M., Larriba J. L. G., Arranz J. A., Redrado M. and Calvo A. (20220201). Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. : European urology oncology.
MLA
Bellmunt Joaquim, Esteban Emilio, Del Muro Xabier García, Sepúlveda Juan Manuel, Maroto Pablo, Gallardo Enrique, Del Alba Aranzazu González, Etxaniz Olatz, Guix Marta, Larriba Jose Luis González, Arranz Jose A, Redrado Miriam and Calvo Alfonso. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. : European urology oncology. 20220201.